InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company’s core products include N11005, a prandial oral insulin; and GemOral. It also offers Imipenem and Cilastatin solution for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents consisting of gadopentetate dimeglumine and gadodiamide; oncology agents comprising Innomustine and Immurin; and Inpheno tablets for rare diseases. In addition, the company provides MUCR system, OralPas, and OralPas Pro technology platform. Its product pipeline comprises D07001, which is in phase I trial for treatment of tumor; C08001, which is in phase lll for the treatment of hypertension, heart failure and left ventricular dysfunction following myocardial infarction; D07002, which is in pilot BE trial used as a supplement for phenylketonuria; and C07001, which is in pilot BE trial for the treatment of parkinson’s disease; N11001, which is in pilot BE as urology agents; and D0131502 and D0051301 as contrast agents and is in formulation. The company was founded in 1994 and is based in Taipei, Taiwan.
Metrics to compare | 4172 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4172PeersSector | |
---|---|---|---|---|
P/E Ratio | −18.0x | −12.9x | −0.5x | |
PEG Ratio | 0.56 | 0.09 | 0.00 | |
Price/Book | 3.0x | 1.9x | 2.6x | |
Price / LTM Sales | 55.5x | 4.8x | 3.1x | |
Upside (Analyst Target) | - | 0.0% | 47.8% | |
Fair Value Upside | Unlock | 2.1% | 6.9% | Unlock |